ReviewFrontiers in oncology2019
The Role of New Technologies in Myeloproliferative Neoplasms.
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- The molecular management of classic myeloproliferative neoplasm.Journal of the Egyptian National Cancer Institute · 2025Review
- Molecular landscape of non-driver genes in myeloproliferative neoplasms through 333 cancer genes panel: Insights to reveal in Pakistan.BMC medical genomics · 2025Article
- Severe Anemia With Intraosseous-Intramuscular Hemorrhage in a Patient With Kit-C-Negative Systemic Mastocytosis.Cureus · 2025Article
- Molecular landscape of theBiomedical reports · 2023Article
- AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.Cancer reports (Hoboken, N.J.) · 2023Article
- Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on theHematology reports · 2023Article
- Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future.Journal of clinical medicine · 2023Review
- Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?Frontiers in medicine · 2023Review
- The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis.Frontiers in oncology · 2023Article
- Mutational Landscape of Patients Referred for Elevated Hemoglobin Level.Current oncology (Toronto, Ont.) · 2022Article
- Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.Molecular diagnosis & therapy · 2022Article
- IGFBP-6: At the Crossroads of Immunity, Tissue Repair and Fibrosis.International journal of molecular sciences · 2022Review
- Review
- Is It Possible to Predict Clonal Thrombocytosis in Triple-Negative Patients with Isolated Thrombocytosis Based Only on Clinical or Blood Findings?Journal of clinical medicine · 2021Article
- Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.Life (Basel, Switzerland) · 2021Review
- Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.International journal of molecular sciences · 2021Review
- Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers.Cancers · 2021Review
- The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.International journal of molecular sciences · 2021Review
- Focus on Osteosclerotic Progression in Primary Myelofibrosis.Biomolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hallmark of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.